HRP20190876T1 - Novi adjuvantirani pripravci - Google Patents
Novi adjuvantirani pripravci Download PDFInfo
- Publication number
- HRP20190876T1 HRP20190876T1 HRP20190876TT HRP20190876T HRP20190876T1 HR P20190876 T1 HRP20190876 T1 HR P20190876T1 HR P20190876T T HRP20190876T T HR P20190876TT HR P20190876 T HRP20190876 T HR P20190876T HR P20190876 T1 HRP20190876 T1 HR P20190876T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- accordance
- felv
- antigen
- avian influenza
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 4
- 239000002671 adjuvant Substances 0.000 title claims 3
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 241000714165 Feline leukemia virus Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 241000282326 Felis catus Species 0.000 claims 2
- 208000002979 Influenza in Birds Diseases 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 206010064097 avian influenza Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 claims 1
- 101900302604 Feline leukemia virus Surface protein Proteins 0.000 claims 1
- 101800001271 Surface protein Proteins 0.000 claims 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/012—Coccidia antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24351—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7623208P | 2008-06-27 | 2008-06-27 | |
| US21455709P | 2009-04-24 | 2009-04-24 | |
| EP15197967.1A EP3056214B1 (en) | 2008-06-27 | 2009-06-24 | Novel adjuvant compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190876T1 true HRP20190876T1 (hr) | 2019-07-12 |
Family
ID=41445049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190876TT HRP20190876T1 (hr) | 2008-06-27 | 2019-05-13 | Novi adjuvantirani pripravci |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8580280B2 (https=) |
| EP (4) | EP3552625A1 (https=) |
| JP (5) | JP5659332B2 (https=) |
| KR (1) | KR101333852B1 (https=) |
| CN (4) | CN104001170B (https=) |
| AR (1) | AR072378A1 (https=) |
| AU (1) | AU2009263759B2 (https=) |
| BR (2) | BRPI0913954B1 (https=) |
| CA (3) | CA2960846C (https=) |
| CL (1) | CL2010001360A1 (https=) |
| CO (1) | CO6331297A2 (https=) |
| CY (2) | CY1117650T1 (https=) |
| DK (2) | DK3056214T3 (https=) |
| ES (2) | ES2569907T3 (https=) |
| HR (1) | HRP20190876T1 (https=) |
| HU (2) | HUE028921T2 (https=) |
| LT (1) | LT3056214T (https=) |
| ME (1) | ME01199B (https=) |
| MX (6) | MX368220B (https=) |
| NZ (5) | NZ589079A (https=) |
| PH (2) | PH12014501836A1 (https=) |
| PL (2) | PL2310046T3 (https=) |
| PT (1) | PT3056214T (https=) |
| RU (1) | RU2510280C2 (https=) |
| SI (2) | SI2310046T1 (https=) |
| TW (4) | TWI513464B (https=) |
| UY (1) | UY31942A (https=) |
| WO (1) | WO2009156960A2 (https=) |
| ZA (1) | ZA201007835B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8444989B1 (en) * | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
| ES2569907T3 (es) * | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
| SI2759306T1 (sl) * | 2008-12-09 | 2016-05-31 | Coley Pharmaceutical Group, Inc. | Imunostimulacijski oligonukleotidi |
| CN102573802A (zh) * | 2009-08-12 | 2012-07-11 | 希格默伊德药业有限公司 | 包含聚合物基质和油相的免疫调节组合物 |
| FR2957803B1 (fr) * | 2010-03-24 | 2012-06-01 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | Diluants adjuvants de vaccins vivants pour maladies porcines |
| EP2575878B1 (en) * | 2010-05-28 | 2018-06-13 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules |
| PE20140576A1 (es) | 2011-06-10 | 2014-05-24 | Novartis Ag | Vacunas bovinas y metodos |
| DK2750683T4 (da) | 2011-10-03 | 2021-04-12 | Croda Int Plc | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser |
| EP4218808A3 (en) * | 2012-03-12 | 2023-08-09 | Advanced BioAdjuvants, LLC | Adjuvant and vaccine compositions |
| PT2938747T (pt) | 2012-12-28 | 2019-08-01 | Boehringer Ingelheim Vetmedica Gmbh | Método de preparação de uma vacina de micoplasma |
| SG11201505086QA (en) | 2012-12-28 | 2015-07-30 | Boehringer Ingelheim Vetmed | Immunogenic composition comprising mycoplasma antigens |
| CN103127495B (zh) * | 2013-01-28 | 2015-04-08 | 重庆市畜牧科学院 | 二联灭活苗的制剂及其制备方法 |
| HK1224177A1 (zh) * | 2013-09-05 | 2017-08-18 | 硕腾服务有限责任公司 | Hendra和nipah病毒g糖蛋白免疫原性組合物 |
| UA130246C2 (uk) * | 2013-09-19 | 2025-12-31 | Зоетіс Сервісіз Ллс | Ад'ювант на основі олії |
| MX2016004961A (es) | 2013-10-17 | 2016-06-28 | Zoetis Services Llc | Procedimientos y composiciones para el tratamiento de infecciones por s. equi. |
| EP4241853B1 (en) | 2013-11-26 | 2026-02-11 | Zoetis Services LLC | Compositions for induction of immune response |
| PL3223846T3 (pl) * | 2014-11-26 | 2024-03-11 | Huvepharma, Inc. | Kompozycje adiuwantowe i powiązane sposoby |
| US10195261B2 (en) | 2014-11-26 | 2019-02-05 | VaxLiant, LLC | Adjuvant compositions and related methods |
| CN115317600A (zh) * | 2015-01-16 | 2022-11-11 | 硕腾服务有限责任公司 | 口蹄疫疫苗 |
| US9636397B2 (en) * | 2015-03-24 | 2017-05-02 | VaxLiant, LLC | Adjuvant compositions and related methods |
| CN104771754B (zh) * | 2015-04-02 | 2018-02-13 | 武汉科前生物股份有限公司 | 一种猪圆环病毒2型灭活疫苗水性佐剂及应用 |
| CN106267183B (zh) * | 2015-06-09 | 2023-02-28 | 普莱柯生物工程股份有限公司 | 含有佐剂的活疫苗组合物及其制备方法和应用 |
| CN106344920B (zh) * | 2015-07-16 | 2020-11-27 | 普莱柯生物工程股份有限公司 | 一种疫苗用佐剂及其应用 |
| US10456459B2 (en) | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| EP3325015B1 (en) * | 2015-07-20 | 2021-05-12 | Zoetis Services LLC | Liposomal adjuvant compositions |
| BR112018007870A2 (pt) * | 2015-10-19 | 2019-01-15 | Cadila Healthcare Ltd | composição imunogênica, método para a preparação de uma composição imunogênica, composição farmacêutica, vacina, método para estimular uma resposta imune em um paciente |
| WO2017123201A1 (en) | 2016-01-11 | 2017-07-20 | Zoetis Services Llc | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
| US11013798B2 (en) | 2016-03-21 | 2021-05-25 | South Dakota Board Of Regents | Orf virus-based platform for vaccine delivery |
| KR20210068602A (ko) | 2016-06-02 | 2021-06-09 | 조에티스 서비시즈 엘엘씨 | 감염성 기관지염에 대한 백신 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
| US10092604B1 (en) * | 2017-12-21 | 2018-10-09 | Bioceuticals Pte. Ltd. | Methods for treatment of skin infectious diseases using microorganisms |
| US11433139B2 (en) | 2018-03-16 | 2022-09-06 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| CN108853493A (zh) * | 2018-07-26 | 2018-11-23 | 中国人民解放军陆军军医大学 | 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用 |
| WO2020023950A1 (en) | 2018-07-27 | 2020-01-30 | Research Development Foundation | Chimeric immunogenic polypeptides |
| WO2020055503A1 (en) * | 2018-09-14 | 2020-03-19 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
| CN109675028A (zh) * | 2019-03-01 | 2019-04-26 | 龙阔（苏州）生物工程有限公司 | 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗 |
| CN114514238A (zh) * | 2019-07-12 | 2022-05-17 | 研究发展基金会 | 埃立克体疫苗和免疫原性组合物 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US20230302079A1 (en) * | 2020-06-19 | 2023-09-28 | Kimberly-Clark Worldwide, Inc. | Saponin containing extracts prepared from hesperaloe useful in the treatment of non-human animals |
| WO2021258056A1 (en) * | 2020-06-19 | 2021-12-23 | Kimberly-Clark Worldwide, Inc. | Saponin containing extracts prepared from hesperaloe useful in the treatment of non-human animals |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| TWI884296B (zh) | 2020-08-11 | 2025-05-21 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
| CN114848807A (zh) * | 2021-02-04 | 2022-08-05 | 洛阳赛威生物科技有限公司 | 一种蜂胶佐剂组合物、及其制备方法以及应用 |
| US20230109193A1 (en) * | 2021-10-02 | 2023-04-06 | Massachusetts Institute Of Technology | Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants |
| EP4665313A1 (fr) * | 2023-02-16 | 2025-12-24 | Vaxinano | Composition vaccinale comprenant un systeme de delivrance d'une bacterie entiere inactivee via des nanoparticules polysaccharidiques cationiques sans adjuvant |
| US12226468B2 (en) | 2023-06-26 | 2025-02-18 | Research Development Foundation | Immunoreactive peptides |
| CN116747312B (zh) * | 2023-07-21 | 2025-08-08 | 辽宁成大生物股份有限公司 | 一种疫苗冻干保护剂、制剂及制备方法 |
| CN121360223A (zh) * | 2024-07-19 | 2026-01-20 | 硕腾服务有限责任公司 | 流感疫苗 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4264587A (en) * | 1979-08-01 | 1981-04-28 | Pedersen Niels C | Vaccine for preventing persistent feline leukemia viremia in cats |
| NZ221306A (en) * | 1986-08-15 | 1990-02-26 | Commw Scient Ind Res Org | 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof |
| US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
| EP0273512B1 (en) | 1986-12-19 | 1991-02-27 | Duphar International Research B.V | Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| RU1615918C (ru) | 1989-05-22 | 1995-07-09 | Всероссийский научно-исследовательский институт защиты животных | Адъювант |
| JPH07502897A (ja) * | 1992-01-06 | 1995-03-30 | ファイザー・インコーポレイテッド | ネコ白血病ウイルスワクチン |
| ZA936095B (en) | 1992-08-21 | 1994-03-14 | Univ Melbourne | Cytokine applications. |
| US6764682B1 (en) | 1994-06-16 | 2004-07-20 | Aventis Pasteur Limited | Adjuvant compositions containing more than one adjuvant |
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| CA2289253A1 (en) * | 1997-04-30 | 1998-11-05 | Merieux Oravax | Anti-helicobacter vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method |
| AU733310C (en) | 1997-05-14 | 2001-11-29 | University Of British Columbia, The | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| EP1003850B1 (en) | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
| KR20010024245A (ko) * | 1997-10-20 | 2001-03-26 | 조지 제이. 리코스 | 네오스포라 백신 |
| EP0953641A3 (en) * | 1998-03-26 | 2002-03-13 | Pfizer Products Inc. | Polynucleotide molecules encoding neospora proteins |
| JP2002514397A (ja) | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧオリゴヌクレオチドを用いる造血調節の方法 |
| SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| PT1104306E (pt) | 1998-08-10 | 2006-05-31 | Antigenics Inc | Composicoes de cpg e adjuvantes de saponina e seus metodos |
| AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
| EP1156781B1 (en) | 1999-02-26 | 2005-06-08 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
| AU4188100A (en) | 1999-04-08 | 2000-11-14 | Gregory M. Glenn | Dry formulation for transcutaneous immunization |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| PT1187629E (pt) | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| EP1177439B1 (en) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening for immunostimulatory dna functional modifiers |
| AU2001227889A1 (en) | 2000-01-14 | 2001-07-24 | The United States of America, represented by The Secretary, Department of Health & Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| JP5025871B2 (ja) | 2000-02-21 | 2012-09-12 | エイチ．リュンドベック エイ／エス | アミロイドの新規なダウン−レギュレート方法 |
| AU5736601A (en) | 2000-05-01 | 2001-11-12 | Hybridon Inc | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
| ES2307568T3 (es) | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
| US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
| US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| CA2439111A1 (en) | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
| US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| WO2002094845A2 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Method for stabilising of nucleic acids |
| EP1395262A4 (en) | 2001-06-15 | 2006-04-12 | Ribapharm Corp | NUCLEOSIDE-VACCINE-ADJUVANTS |
| WO2003004051A2 (en) | 2001-07-02 | 2003-01-16 | Pfizer Products Inc. | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| WO2003003941A2 (en) | 2001-07-02 | 2003-01-16 | Pfizer Products Inc. | One dose vaccination with mycoplasma hyopneumoniae |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| CA2456193A1 (en) | 2001-08-03 | 2003-03-27 | Medarex, Inc. | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| US20030133988A1 (en) | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
| US20030138434A1 (en) | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
| ATE411054T1 (de) | 2001-08-17 | 2008-10-15 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
| IL159145A0 (en) | 2001-08-28 | 2004-06-01 | Pfizer Prod Inc | Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions |
| DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| US20030119774A1 (en) | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
| GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
| US20050238660A1 (en) | 2001-10-06 | 2005-10-27 | Babiuk Lorne A | Cpg formulations and related methods |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| EP1441763A2 (en) | 2001-11-07 | 2004-08-04 | Inex Pharmaceuticals Corp. | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
| AU2002358616A1 (en) | 2001-12-07 | 2003-06-17 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| WO2003066649A1 (en) | 2002-02-04 | 2003-08-14 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| EP1476456A4 (en) | 2002-02-19 | 2007-06-20 | Syntherica Corp | COMPOSITIONS AND METHOD FOR SUBROGEN-ANTIBODY MODULATION OF AN IMMUNE RESPONSE AND TRANSPORT |
| EP3006043B1 (en) | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
| WO2003089590A2 (en) | 2002-04-16 | 2003-10-30 | Vaxin, Inc. | TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH |
| KR101092043B1 (ko) | 2002-04-22 | 2011-12-12 | 바이오니취 라이프 사이언시즈 인코포레이티드 | 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도 |
| KR100456681B1 (ko) | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물 |
| CA2487452A1 (en) | 2002-05-28 | 2003-12-04 | Robinson Ramirez-Pineda | A method for generating antigen-presenting cells |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| SE0201701D0 (sv) | 2002-06-05 | 2002-06-05 | Gotovax Ab | Treatment of epithelial tumors and infections |
| US20040009949A1 (en) | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| EP1575504A4 (en) | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES |
| TWI314134B (en) | 2002-11-05 | 2009-09-01 | James Hardie Int Finance Bv | Calcium silicate hydrate and the method for producing the same |
| MXPA05008051A (es) * | 2003-01-29 | 2005-09-21 | Pfizer Prod Inc | Vacunas caninas contra bordetella bronchiseptica. |
| AU2003900767A0 (en) * | 2003-02-21 | 2003-03-13 | St Vincent's Hospital Sydney Limited | Idiotypic vaccine |
| AU2004224761A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| AU2004226591B2 (en) | 2003-04-04 | 2009-06-04 | Zoetis Services Llc | Microfluidized oil-in-water emulsions and vaccine compositions |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| JP5600375B2 (ja) * | 2004-03-09 | 2014-10-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | インフルエンザウイルスワクチン |
| KR20110132416A (ko) * | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| JP2008515813A (ja) * | 2004-10-06 | 2008-05-15 | アグリ−バイオテック ピーティーワイ リミテッド | 抗体産生方法 |
| GB0426481D0 (en) * | 2004-12-02 | 2005-01-05 | Vaccine Technology Ltd | Composition |
| WO2006106424A2 (en) * | 2005-04-07 | 2006-10-12 | Pharmacia & Upjohn Company Llc | Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines |
| AU2006241149A1 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| ME00485B (me) * | 2005-10-07 | 2011-10-10 | Zoetis Services Llc | VAKCINE l METODE LIJEČENJA INFLUENCE KOD CANINA |
| CA2631714C (en) * | 2005-12-02 | 2014-09-16 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| CA2634888C (en) | 2006-01-26 | 2016-06-21 | Pfizer Products Inc. | Novel glycolipid adjuvant compositions |
| WO2007089753A2 (en) * | 2006-01-26 | 2007-08-09 | Hx Diagnostics, Inc. | Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof |
| JP2010512748A (ja) * | 2006-12-15 | 2010-04-30 | シェーリング−プラウ・リミテッド | インフルエンザウイルスを培養物中で複製するための方法 |
| WO2008074487A2 (en) * | 2006-12-19 | 2008-06-26 | Novosom Ag | Lipids and lipid assemblies comprising transfection enhancer elements |
| US20080292663A1 (en) | 2007-05-22 | 2008-11-27 | Gerber Jay D | Adjuvant compositions and methods for delivering vaccines |
| CL2008001806A1 (es) | 2007-06-20 | 2008-09-05 | Wyeth Corp | Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion. |
| ES2569907T3 (es) * | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| CA2753567C (en) | 2009-02-27 | 2019-12-31 | Toray Industries, Inc. | Immunogenic antigen-adjuvant microparticle complex |
| US10456459B2 (en) * | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
-
2009
- 2009-06-24 ES ES09769768.4T patent/ES2569907T3/es active Active
- 2009-06-24 CN CN201410198333.XA patent/CN104001170B/zh active Active
- 2009-06-24 NZ NZ589079A patent/NZ589079A/xx unknown
- 2009-06-24 KR KR1020107029087A patent/KR101333852B1/ko active Active
- 2009-06-24 MX MX2016016408A patent/MX368220B/es unknown
- 2009-06-24 ES ES15197967T patent/ES2728949T3/es active Active
- 2009-06-24 NZ NZ727616A patent/NZ727616A/en unknown
- 2009-06-24 PL PL09769768.4T patent/PL2310046T3/pl unknown
- 2009-06-24 RU RU2010149495/15A patent/RU2510280C2/ru active
- 2009-06-24 MX MX2016016410A patent/MX375202B/es unknown
- 2009-06-24 BR BRPI0913954-0A patent/BRPI0913954B1/pt active IP Right Grant
- 2009-06-24 NZ NZ709547A patent/NZ709547A/en unknown
- 2009-06-24 SI SI200931399A patent/SI2310046T1/sl unknown
- 2009-06-24 CN CN201510098559.7A patent/CN104758929B/zh active Active
- 2009-06-24 CA CA2960846A patent/CA2960846C/en active Active
- 2009-06-24 CA CA2960734A patent/CA2960734C/en active Active
- 2009-06-24 PT PT15197967T patent/PT3056214T/pt unknown
- 2009-06-24 CA CA2723786A patent/CA2723786C/en active Active
- 2009-06-24 ME MEP-2010-194A patent/ME01199B/me unknown
- 2009-06-24 AU AU2009263759A patent/AU2009263759B2/en active Active
- 2009-06-24 DK DK15197967.1T patent/DK3056214T3/da active
- 2009-06-24 NZ NZ621834A patent/NZ621834A/en unknown
- 2009-06-24 JP JP2011515706A patent/JP5659332B2/ja active Active
- 2009-06-24 US US12/490,767 patent/US8580280B2/en active Active
- 2009-06-24 SI SI200931968T patent/SI3056214T1/sl unknown
- 2009-06-24 EP EP19166434.1A patent/EP3552625A1/en not_active Withdrawn
- 2009-06-24 MX MX2010014026A patent/MX2010014026A/es active IP Right Grant
- 2009-06-24 MX MX2013014772A patent/MX344311B/es unknown
- 2009-06-24 HU HUE09769768A patent/HUE028921T2/en unknown
- 2009-06-24 DK DK09769768.4T patent/DK2310046T3/da active
- 2009-06-24 CN CN200980124560.5A patent/CN102076358B/zh active Active
- 2009-06-24 PL PL15197967T patent/PL3056214T3/pl unknown
- 2009-06-24 HU HUE15197967A patent/HUE043493T2/hu unknown
- 2009-06-24 EP EP15197967.1A patent/EP3056214B1/en active Active
- 2009-06-24 MX MX2013014771A patent/MX349720B/es unknown
- 2009-06-24 EP EP09769768.4A patent/EP2310046B1/en active Active
- 2009-06-24 WO PCT/IB2009/052724 patent/WO2009156960A2/en not_active Ceased
- 2009-06-24 LT LTEP15197967.1T patent/LT3056214T/lt unknown
- 2009-06-24 NZ NZ602945A patent/NZ602945A/en unknown
- 2009-06-24 EP EP20169980.8A patent/EP3725328A3/en active Pending
- 2009-06-24 BR BR122021025097-9A patent/BR122021025097B1/pt active IP Right Grant
- 2009-06-24 CN CN201410197979.6A patent/CN104001169B/zh active Active
- 2009-06-26 UY UY0001031942A patent/UY31942A/es not_active Application Discontinuation
- 2009-06-26 TW TW098121642A patent/TWI513464B/zh active
- 2009-06-26 TW TW104123871A patent/TWI622400B/zh active
- 2009-06-26 TW TW104123873A patent/TWI614027B/zh active
- 2009-06-26 AR ARP090102382A patent/AR072378A1/es not_active Application Discontinuation
- 2009-06-26 TW TW104123872A patent/TWI622401B/zh active
-
2010
- 2010-11-02 ZA ZA2010/07835A patent/ZA201007835B/en unknown
- 2010-12-06 CL CL2010001360A patent/CL2010001360A1/es unknown
- 2010-12-16 MX MX2019011253A patent/MX2019011253A/es unknown
- 2010-12-22 CO CO10160889A patent/CO6331297A2/es not_active Application Discontinuation
-
2013
- 2013-08-29 US US14/013,299 patent/US9662385B2/en active Active
-
2014
- 2014-01-24 JP JP2014011040A patent/JP5882370B2/ja active Active
- 2014-01-24 JP JP2014011047A patent/JP5824538B2/ja active Active
- 2014-08-14 PH PH12014501836A patent/PH12014501836A1/en unknown
- 2014-08-14 PH PH12014501835A patent/PH12014501835A1/en unknown
-
2015
- 2015-03-17 JP JP2015053170A patent/JP6038211B2/ja active Active
-
2016
- 2016-05-30 CY CY20161100466T patent/CY1117650T1/el unknown
- 2016-10-26 JP JP2016209399A patent/JP6294938B2/ja active Active
-
2017
- 2017-04-26 US US15/494,920 patent/US10238736B2/en active Active
-
2018
- 2018-03-23 US US15/933,805 patent/US10940202B2/en active Active
-
2019
- 2019-05-13 HR HRP20190876TT patent/HRP20190876T1/hr unknown
- 2019-06-04 CY CY20191100589T patent/CY1121789T1/el unknown
-
2021
- 2021-03-08 US US17/195,003 patent/US11896666B2/en active Active
-
2024
- 2024-01-08 US US18/406,869 patent/US12521433B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190876T1 (hr) | Novi adjuvantirani pripravci | |
| WO2007124479A3 (en) | Avian influenza viruses, vaccines, compositions, formulations, and methods | |
| MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| JP2009539965A5 (https=) | ||
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| JP2011504486A5 (https=) | ||
| WO2009092038A8 (en) | Influenza dna vaccination and methods of use thereof | |
| BR112016006192A2 (pt) | composição de vacina de divergente de pcv2b e métodos de uso | |
| HRP20140488T1 (hr) | Cjepivo protiv influence | |
| JP2013533259A5 (https=) | ||
| MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
| BR112015002549A2 (pt) | regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas | |
| BR112012022939A2 (pt) | composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza | |
| Dong et al. | Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice | |
| JP2013522231A5 (https=) | ||
| EA201491969A1 (ru) | Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197 | |
| CO6280408A2 (es) | Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma | |
| EA201500140A1 (ru) | Ослабленные вакцины от свиного гриппа и способы их получения и применения | |
| JP2006512078A5 (https=) | ||
| MX2019012620A (es) | Composiciones de vacunas. | |
| RU2014140168A (ru) | Улучшенная вакцинация против гриппа | |
| RU2013135887A (ru) | Композиции для комплекса респираторных заболеваний собак | |
| WO2008115785A3 (en) | Multivalent avian influenza vaccines and methods | |
| EA201070014A1 (ru) | Внутрикожная вакцина против гриппа |